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Mutations in the nuclear-encoded mitochondrial maintenance gene RRM2B are an important cause of familial mitochondrial
disease in both adults and children and represent the third most common cause of multiple mitochondrial DNA deletions in
adults, following POLG [polymerase (DNA directed), gamma] and PEO1 (now called C10ORF2, encoding the Twinkle helicase)
mutations. However, the clinico-pathological and molecular features of adults with RRM2B-related disease have not been clearly
defined. In this multicentre study of 26 adult patients from 22 independent families, including five additional cases published in
the literature, we show that extra-ocular neurological complications are common in adults with genetically confirmed RRM2B
mutations. We also demonstrate a clear correlation between the clinical phenotype and the underlying genetic defect. Myopathy
was a prominent manifestation, followed by bulbar dysfunction and fatigue. Sensorineural hearing loss and gastrointestinal
disturbance were also important findings. Severe multisystem neurological disease was associated with recessively inherited
compound heterozygous mutations with a mean age of disease onset at 7 years. Dominantly inherited heterozygous mutations
were associated with a milder predominantly myopathic phenotype with a later mean age of disease onset at 46 years. Skeletal
muscle biopsies revealed subsarcolemmal accumulation of mitochondria and/or cytochrome c oxidase-deficient fibres. Multiple
mitochondrial DNA deletions were universally present in patients who underwent a muscle biopsy. We identified 18 different
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heterozygous RRM2B mutations within our cohort of patients, including five novel mutations that have not previously been
reported. Despite marked clinical overlap between the mitochondrial maintenance genes, key clinical features such as bulbar
dysfunction, hearing loss and gastrointestinal disturbance should help prioritize genetic testing towards RRM2B analysis, and
sequencing of the gene may preclude performance of a muscle biopsy.
Keywords: mitochondrial DNA; mtDNA maintenance; mtDNA depletion; multiple mitochondrial DNA deletions; RRM2B
Abbreviations: COX = cytochrome c oxidase; dNTP = deoxyribonucleoside triphosphate; PEO = progressive external
ophthalmoplegia; SDH = succinate dehydrogenase
Introduction
Approximately one-half of all adult mitochondrial diseases result
from genetic dysfunction of the nuclear-encoded mitochondrial
genes. A significant number of these cases are due to disruption
of genes involved in maintenance (replication and repair) of mito-
chondrial DNA, leading to qualitative (accumulation of multiple
mitochondrial DNA deletions) and/or quantitative (depletion of
mitochondrial DNA copy number) downstream mitochondrial gen-
omic effects. To date, almost all known nuclear maintenance
genes fall into one of two categories: (i) genes whose protein
products function directly at the mitochondrial DNA replication
fork (Van Goethem et al., 2001; Spelbrink et al., 2001; Longley
et al., 2006); or (ii) genes that encode proteins involved in sup-
plying mitochondria with deoxyribonucleoside triphosphate (dNTP)
pools required for DNA replication (Nishino et al., 1999; Kaukonen
et al., 2000; Mandel et al., 2001; Saada et al., 2001; Bourdon
et al., 2007; Ostergaard et al., 2007; Fratter et al., 2011). The
most common presenting neurological feature seen in adults with
mitochondrial DNA maintenance disorders is progressive external
ophthalmoplegia (PEO) and ptosis. Of the 12 known maintenance
genes, eight have been associated with PEO, although the clinical
phenotype is not necessarily restricted to the extra-ocular muscles.
Ribonucleotide reductase M2B (TP53 inducible), RRM2B (MIM
604 712), encodes the p53-inducible small subunit (p53R2) of
ribonucleotide reductase, a heterotetrameric enzyme that catalyses
de novo syntheses of dNTPs by direct reduction of ribonucleoside
diphosphates to their corresponding deoxyribonucleoside diphos-
phates. This process supplements the dNTPs produced by the
mitochondrion’s own dNTP salvage pathway, defects of which
cause many of the mitochondrial DNA depletion syndromes
(Rahman and Poulton, 2009), and is essential for mitochondrial
DNA synthesis. Transcription of RRM2B is tightly regulated by
the tumour suppressor protein p53. Mutations in the gene have
been associated with both recessively and dominantly inherited
mitochondrial disease. Spliced variant transcripts have also been
reported (Spinazzola et al., 2009).
The first reported human diseases linked to RRM2B dysfunction
were associated with mitochondrial DNA depletion (Bourdon
et al., 2007; Bornstein et al., 2008; Acham-Roschitz et al.,
2009; Kolberg et al., 2009; Spinazzola et al., 2009) and caused
severe, early-onset, multisystem disease with infant mortality.
RRM2B mutations have since been recognized to cause
adult-onset syndromes. This was first demonstrated in a patient
with mitochondrial neurogastrointestinal encephalopathy and
mitochondrial DNA depletion (Shaibani et al., 2009). Tyynismaa
et al. (2009) later published about a large autosomal-dominant
PEO family with multiple mitochondrial DNA deletions whose
disease was not explained by mutations in any of the known
autosomal-dominant PEO genes. The disease locus in the family
was mapped using genome-wide linkage and found to contain
RRM2B, and a heterozygous nonsense mutation in exon 9 was
detected and demonstrated in another unrelated family. The
mutant messenger RNA was shown to escape nonsense-mediated
decay and resulted in a truncated protein that was postulated to
cause a dominant-negative or gain-of-function effect on the het-
erotetrameric structure of the ribonucleotide reductase enzyme.
The mechanistic importance of truncating exon 9 mutations was
further expanded by Fratter et al. (2011), who showed that three
further novel pathogenic variants in exon 9 caused familial auto-
somal-dominant PEO in seven unrelated probands. In addition,
clinically more severe, recessively inherited, compound heterozy-
gous mutations were demonstrated. Kearns–Sayre syndrome re-
sulting from compound heterozygous RRM2B mutations with
secondary multiple mitochondrial DNA deletions has also been
reported, thus confirming the more severe nature of recessively
inherited adult RRM2B mutations and expanding the clinical
phenotype associated with RRM2B-related mitochondrial disease
beyond that of PEO and PEO-plus syndromes (Pitceathly et al.,
2011).
Despite emerging evidence that RRM2B mutations are the third
most common cause of multiple mitochondrial DNA deletions in
adults, following POLG and PEO1 (now known as C10ORF2)
(Fratter et al., 2011; Pitceathly et al., 2011), and RRM2B dysfunc-
tion being an important cause of neurological disease, the adult
phenotypic and molecular spectrum is not fully understood. We,
therefore, conducted a systematic clinical and molecular study of
adult patients with RRM2B mutation(s) to define the phenotypic
spectrum of adult RRM2B-related mitochondrial disease and es-
tablish any genotype–phenotype correlations.
Materials and methods
Patient cohorts
Newcastle–Oxford–Halle cohort
We selected a cohort of adult patients who had been referred to the
NHS Specialized Services-funded Mitochondrial Diagnostic Centres in
Newcastle and Oxford, UK, or the Mitochondrial Centre in Halle,
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Germany, for investigation of suspected mitochondrial disease, owing
to their clinical presentation, evidence of a mitochondrial biochemical
defect and/or presence of mitochondrial DNA deletions. RRM2B
sequencing was performed when initial screens for POLG, POLG2,
PEO1 and SLC25A4 were found to be negative.
The subject’s consent was obtained according to the Declaration of
Helsinki, and institutional ethical committee approval was obtained at
each centre in which the work was performed.
Additional published adult cases
We conducted a systematic review of the literature to identify all pre-
viously published adult cases with confirmed RRM2B mutations. These
were included in our analysis to determine the complete clinical spec-
trum and genotype–phenotype correlates seen in adult RRM2B-related
mitochondrial disease (Shaibani et al., 2009; Tyynismaa et al., 2009;
Fratter et al., 2011; Pitceathly et al., 2011; Takata et al., 2011).
Phenotypic evaluation
To define the extent and severity of patient’s mitochondrial disease,
a neurologist at each centre comprehensively assessed each patient
harbouring pathogenic RRM2B mutations and/or examined their
medical records.
Mitochondrial histochemistry
Skeletal muscle biopsies were collected from 21 patients with patho-
genic RRM2B mutations. Cryostat sections (10 mm) were cut from
transversely oriented muscle blocks and subjected to cytochrome c
oxidase (COX), succinate dehydrogenase (SDH) and sequential COX-
SDH histochemical staining to assess the numbers of COX-deficient
fibres as a measure of respiratory chain deficiency, as previously
described (Taylor et al., 2004). The SDH reaction was used to ascer-
tain the number of fibres exhibiting increased levels of enzyme activity
in the subsarcolemmal region, namely, ‘ragged-blue’ fibres, in addition
to data obtained from the histological modified Gomori trichrome
stain.
Mitochondrial DNA analysis
Where available, total muscle DNA was extracted by standard tech-
niques and screened for mitochondrial DNA rearrangements by South-
ern blotting and/or long-range PCR protocols, as described previously
(Murphy et al., 2008). The presence of clonally expanded mitochon-
drial DNA deletions in individual COX-positive and COX-deficient
fibres was further screened in muscle biopsies from nine patients
with either dominantly inherited or recessively inherited RRM2B mu-
tations (Patients 1.1, 3, 5, 9, 10, 14, 19 and 20), by previously pub-
lished protocols, using primers and TaqMan probes to assess the
simultaneous amplification of the MTND1 (rarely deleted) and
MT-ND4 (often deleted) genes (He et al., 2002; Krishnan et al.,
2007). Absence of mitochondrial DNA depletion in muscle was con-
firmed in all cases by real-time quantitative PCR, as described previ-
ously (Blakeley et al., 2008).
Identification of pathogenic RRM2B
mutations
The coding exons and intron–exon boundaries of RRM2B (GenBank
accession number NM_015713) were sequenced, as previously
described (Tyynismaa et al., 2009). RRM2B exon copy number
(exons 1–8) was assessed by multiplex ligation-dependent probe amp-
lification (MRC-Holland kit P089-A1) in all patients with dominantly
inherited heterozygous missense RRM2B mutations. Total RNA from
patients with the c.48G4A RRM2B variant (Patients 1, 1.1 and 2) was
extracted from Ethylenediaminetetraacetic acid-blood with the
QIAamp RNA Blood Mini kit (Qiagen) and reverse transcribed
using the ThermoScriptTM RT-PCR system (Invitrogen). The resulting
complementary DNA was PCR-amplified across the RRM2B exon 1–2
boundary using exonic primers, leading to a normally spliced 303-bp
product. The PCR products were separated by agarose gel electro-
phoresis under standard conditions. Gel stabs of discreet bands were
taken for secondary PCR using the same primers, which were
M13-tagged for subsequent dideoxy Sanger sequencing using univer-
sal M13 primers, BigDye Terminator kit 3.1 (Applied Biosystems) and
capillary electrophoresis on an ABI Prism 3730 Genetic Analyser.
Modelling missense RRM2B mutations
on the p53R2 crystal structure
The 2.6 A˚ X-ray crystal structure of human p53R2 (Research Colla-
boratory for Structural Bioinformatics Protein Data Bank: reference
3HF1) (Smith et al., 2009) was viewed in ViewerLite v.4.2 (Accelrys
Inc.), and the amino acids known to have been substituted were iso-
lated and saved as a separate pdb file. The p53R2 crystal structure and
the isolated amino acids were then rendered using PyMOL v.0.97
(Warren L. DeLano ‘The PyMOL Molecular Graphics System’
DeLano Scientific LLC, http://www.pymol.org).
Results
Patient cohorts
Clinical data are presented on 31 patients (Table 1). Twenty-six
patients were identified by the NHS Specialized Services-funded
Mitochondrial Diagnostic Centres in Newcastle and Oxford, UK, or
the Mitochondrial Centre in Halle, Germany (Newcastle–Oxford–
Halle cohort), and are described here in greater clinical and mo-
lecular detail. Clinical information from five further patients was
obtained from the literature review. One previously published case
(Patient 12, Fratter et al., 2011) was omitted from the current
analysis, as the pathogenic nature of the reported heterozygous
mutation was uncertain after segregation studies.
Newcastle–Oxford–Halle cohort
The clinical and molecular features of all 26 patients from our
Newcastle–Oxford–Halle cohort are summarized in Table 2.
Molecular data from 11 of these subjects have been previously
reported in brief (Fratter et al., 2011). The mean whole-group age
at onset was 40 years (age range birth–70 years); patients with
autosomal-recessive PEO presented considerably earlier at 7 years
(age range birth–14 years), whereas those with autosomal-dom-
inant PEO presented later in the fifth decade of life (mean age of
onset 46 years; age range 15–70 years).
Additional published adult cases
A systematic review of the literature to date (June 1, 2012) re-
vealed published data on 18 RRM2B-positive adult families
(Supplementary Table 1). Thirty-three individuals have been
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extensively genotyped and harbour RRM2B gene mutations char-
acterized by either autosomal-recessive mitochondrial DNA deple-
tion syndrome (Shaibani et al., 2009) or recessive and dominant
mutations that cause the accumulation of multiple mitochondrial
DNA deletions (Tyynismaa et al., 2009; Fratter et al., 2011;
Pitceathly et al., 2011; Takata et al., 2011).
Major clinical features
Evaluation of the clinical features of all 31 adult patients harbour-
ing pathogenic RRM2B mutations showed that PEO was universal
and frequently associated with ptosis (28 patients). Neuromuscular
features were common and included proximal muscle weakness
(16 patients), bulbar dysfunction (13 patients) and fatigue (11
patients). Additional neurological manifestations included ataxia
(12 patients) and sensorineural hearing loss (11 patients).
Non-neurological sequelae such as gastrointestinal disturbance,
including irritable bowel syndrome-like symptoms and low body
mass index (six patients), and endocrinopathy, specifically hypo-
thyroidism, hypoparathyroidism, diabetes and hypogonadism
(seven patients), were also important clinical findings.
Malignancy was detected in two patients (Patients 12 and 18).
Other less common problems included cognitive impairment
(four patients); cardiac dysfunction, including non-fatal arrhythmia
and diastolic dysfunction (two patients); encephalopathy and
stroke-like events (three patients); cataracts (two patients); mi-
graine (two patients); renal disturbance (three patients); distal
muscle weakness (one patient); neuropathy (three patients); pig-
mentary retinopathy (two patients); short stature (one patient);
glaucoma (one patient) and depression (three patients).
Mitochondrial histochemical studies
Twenty-one patients with confirmed RRM2B mutations under-
went a diagnostic muscle biopsy for the investigation of suspected
mitochondrial disease. Patient 6.1 was diagnosed on the basis of
RRM2B gene screening of a blood-derived DNA sample without
performing a muscle biopsy. All showed histochemical evidence of
a COX mosaic defect, with many exhibiting evidence of subsarco-
lemmal mitochondrial accumulation (ragged-red or ragged-blue
fibres) after Gomori trichrome staining or SDH enzyme histochem-
istry. The severity of the associated COX mosaic defect varied
widely, with a more pronounced histochemical defect associated
with autosomal-recessive RRM2B mutations than autosomal-dom-
inant mutations (Fig. 1).
Mitochondrial DNA deletion analysis
All 21 patients who underwent muscle biopsy had multiple mito-
chondrial DNA deletions detectable either by long-range PCR
assays across the major mitochondrial DNA arc (Fig. 2) or by
Southern blot analysis (undertaken in 11 of the 21 patients, with
positive findings reported in all). A small number of patients (five
patients with autosomal-dominant missense or truncating RRM2B
mutations, one patient with an autosomal-dominant splicing
defect and two patients with autosomal-recessive RRM2B muta-
tions) were also investigated by real-time PCR to further charac-
terize the presence of clonally expanded mitochondrial DNA
deletions within single muscle fibres (Fig. 2). In all cases, the ma-
jority of COX-deficient fibres revealed very high levels (480%
mutated mitochondrial DNA) of clonally expanded mitochondrial
DNA deletion involving the MT-ND4 gene region (He et al.,
2002), whereas all COX-positive reacting fibres had lower levels
of mitochondrial DNA deletion. No difference in the distribution of
mitochondrial DNA deletion levels was observed between different
RRM2B mutation types.
Identification of pathogenic RRM2B
mutations
We identified 18 (12 dominantly and six recessively inherited)
different RRM2B mutations within our cohort of patients, includ-
ing five novel mutations that have not previously been reported
(Fig. 3). Thirteen mutations were missense variants predicted to
alter conserved amino acids (Supplementary Fig. 1), four were
truncating mutations in exon 9 and one was a novel c.48G4A
variant predicted to cause aberrant splicing.
Eleven patients (from nine families) were found to have truncat-
ing mutations in exon 9 of RRM2B, three with the p.Leu317X
mutation, one with a p.Glu318X mutation, five with a
p.Asn322LysfsX4 frameshift mutation and two patients from one
family (Patient 17 and her clinically affected daughter, Patient
17.1) with the p.Arg327X mutation, which was the first mutation
in this gene to be described as a cause of autosomal-dominant
Table 1 Summary of clinical data from 31 patients with
pathogenic RRM2B mutations
Clinical presentation Number of
patients
Per cent of
all patients
Ophthalmoparesis 31 100
Ptosis 28 90
Proximal muscle weakness 16 52
Bulbar dysfunction 13 42
Ataxia 12 39
Fatigue 11 36
Sensorineural hearing loss 11 36
Endocrinopathy 7 23
Gastrointestinal disturbance 6 19
Cognitive impairment/learning
difficulties
4 13
Encephalopathy/stroke-like
episode
3 10
Renal disturbance 3 10
Depression 3 10
Neuropathy 2 6
Pigmented retinopathy 2 6
Cardiac dysfunction/arrhythmia 2 6
Cataracts 2 6
Migraine 2 6
Distal muscle weakness 1 3
Glaucoma 1 3
Short stature 1 3
Spectrum of RRM2B mutations in adults Brain 2012: 135; 3392–3403 | 3395
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PEO (Tyynismaa et al., 2009). All nine probands had affected
family members and a family history consistent with a dominantly
inherited disorder (Table 2). Eight patients (from seven families)
harboured single heterozygous RRM2B missense changes, imply-
ing autosomal-dominant inheritance. In all seven families, multi-
plex ligation-dependent probe amplification was used to exclude
exonic copy number variation in trans, with further supporting
evidence of pathogenicity provided by the fact that these changes
affected conserved residues (Supplementary Fig. 1). Four of these
RRM2B mutations were unreported. Patient 4 harboured a novel
p.Arg41Trp mutation, and although there was no relevant family
history to support dominant transmission, mutation of this particu-
lar amino acid (p.Arg41Gln) was reported in another patient
(Patient 3). Patient 5 had a novel p.Asp70Asn mutation and a
clinically affected sister. Patient 18 had a novel mutation
(p.Ala349Gly) in exon 9, which is a recognized mutation hotspot
(Fratter et al., 2011). The single heterozygous p.Ile224Ser muta-
tion reported in Patient 8 is of particular interest, given that it has
previously been reported as a recessive RRM2B mutation in a case
of mitochondrial DNA depletion myopathy (Bornstein et al., 2008)
and, as such, seems to be able to behave as either a recessive or
dominant allele. Similarly, p.Arg41Gln and p.Arg211Lys function
as dominant alleles in Patients 3 and 7, respectively, but have also
been identified in compound heterozygotes with more severe re-
cessively inherited disease (Pitceathly et al., 2011; and Patient 21).
Four patients harboured two recessively inherited compound het-
erozygous RRM2B mutations associated with an earlier onset of
disease and more pronounced COX histochemical defects (Fig. 1
and Table 2). The p.Thr144Ile and p.Gly273Ser mutations were
Figure 2 Characterization of multiple mitochondrial DNA deletions in muscle from patients with RRM2B mutations. (A) Representative
long-range PCR amplification (15.4-kb fragment) across the major mitochondrial DNA arc shows evidence of multiple mitochondrial DNA
deletions in patient muscle. Lane 1, size marker; Lane 2, Patient 5; Lane 3, Patient 10; Lane 4, Patient 19; Lane 5, Patient 20; Lane 6,
Control subject. Patients with autosomal-dominant mutations (Lanes 2 and 3) show amplification of wild-type full-length mitochondrial
DNA amplimers in addition to mitochondrial DNA deletions, whereas those with recessive RRM2B mutations (Patients 19 and 20) display a
more severe secondary mitochondrial DNA defect. (B) Quantitative single-fibre real-time-PCR reveals the majority, but not all, of
COX-deficient fibres contain high levels of a clonally expanded mitochondrial DNA deletion involving the MT-ND4 gene. Autosomal-
dominant missense or truncating mutations are represented by Patients 3, 5, 9, 10 and 14. Patient 1.1 has a dominant splicing mutation,
whereas Patients 19 and 20 harbour recessive RRM2B mutations.
Figure 1 Mitochondrial histochemical changes associated with
RRM2B mutations. Representative sequential COX-SDH histo-
chemistry demonstrates a mosaic distribution of COX-deficient
muscle fibres (blue) among fibres exhibiting normal COX activity
(brown). Illustrated are the images for (A) Patient 5, (B) Patient
10, (C) Patient 19 and (D) Patient 20. Patients 5 and 10 have
autosomal-dominant RRM2B mutations and a milder histo-
chemical COX defect compared with Patients 19 and 20
(autosomal-recessive RRM2B mutations), in whom a more
severe biochemical defect is clearly apparent.
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reported in trans in two of the four patients, whereas the
p.Arg186Gly and p.Thr218Ile mutations (Patient 20) were both
novel. Within this family, the p.Thr218Ile mutation was detected
in the heterozygous state in the clinically unaffected mother and a
sister, whereas the second heterozygous mutation, p.Arg186Gly,
was identified in another clinically unaffected sister. Segregation
studies were also performed in the family of Patient 19; the
p.Gly273Ser mutation was seen in the heterozygous state in the
clinically unaffected mother, whereas a clinically unaffected sister
was heterozygous for the p.Thr144Ile mutation alone. Paternal
testing was not performed.
Finally, an unreported c.48G4A RRM2B variant was identified
in three patients (Patients 1, 1.1 and 2). This is not predicted to
alter the amino acid sequence, resulting in a predicted p.Glu16Glu
synonymous change. However, it was noted that the c.48G4A
variant occurs at the last nucleotide of exon 1 and was therefore
considered likely to result in aberrant splicing (Fig. 4). Analysis of
blood RNA extracted from Patients 1, 1.1 and 2 across the exon
1–2 junction demonstrated that normally spliced RNA arises ex-
clusively from the normal c.48G allele (Fig. 4). Furthermore, the
three patients had additional RNA species associated with the
c.48G4A allele, in which various portions of the 50 region of
intron 1 were retained, resulting in the introduction of a termin-
ation codon, 26 codons beyond exon 1. All three patients had
RNA incorporating the first 268 nucleotides of intron 1. Patient
1.1 also had RNA with the first 518 nucleotides of intron 1, and
Patient 1 also had RNA with the first 467 and 518 nucleotides of
intron 1 (Fig. 4). Thus, these results demonstrate that c.48G4A
abolishes normal splicing of exons 1 to 2, leading to partial intron
retention and premature termination of translation, thereby con-
firming pathogenicity of c.48G4A.
Discussion
RRM2B mutations are emerging as one of the leading causes of
both paediatric and adult-onset mitochondrial disease associated
with disruption of mitochondrial DNA maintenance. RRM2B mu-
tations represent the third most common cause of Mendelian PEO
and multiple mitochondrial DNA deletions in adults (13%), follow-
ing mutations in POLG (27%) and PEO1 (14%), based on data
from both Oxford and Newcastle centres. It is clear there is sig-
nificant clinical overlap between the multiple mitochondrial main-
tenance genes. In our cohort, ophthalmoparesis was universal,
usually severe and often associated with ptosis (90% of patients).
Other prominent myopathic features included proximal muscle
weakness (52% of patients) and bulbar dysfunction (42% of pa-
tients). The latter manifested as dysarthria, dysphagia, dysphonia,
facial weakness and neck weakness. Sensorineural hearing loss
(36% of patients) and gastrointestinal disturbance (19% of pa-
tients), including irritable bowel syndrome-like symptoms and
low body mass index, were also relatively common findings. This
is perhaps unsurprising, given that they are prominent features in
children with mitochondrial DNA depletion secondary to RRM2B
mutations. The presence of significant bulbar weakness, hearing
loss and gastrointestinal symptoms should guide clinicians towards
RRM2B genetic analysis before POLG and PEO1, given that these
key features are more common components of the clinical spec-
trum (bulbar dysfunction 42% versus 37% and 12%; sensori-
neural hearing loss 36% versus 11% and 9%; and
gastrointestinal symptoms 19% versus unreported and 9% in
RRM2B versus POLG and PEO1-related PEO syndromes, respect-
ively) (Horvath et al., 2006; Fratter et al., 2011).
Figure 3 Schematic representation of the RRM2B gene structure illustrating the 18 different mutations identified in this study. Coding
exons are numbered 1–9. Missense mutations are shown in pink boxes, exon 9 truncating mutations are shown in green boxes and the
c.48G4A splice mutation is shown in a yellow box. RRM2B mutations associated with autosomal-dominant PEO (adPEO) in this study,
which have also been associated with more severe autosomal-recessive disease [either early-onset autosomal-recessive PEO (arPEO) or
mitochondrial DNA depletion syndrome], are highlighted in red. Novel unreported RRM2B mutations are highlighted in blue.
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Although cerebellar ataxia was present in 39% of cases, other
central features of mitochondrial disease were seen less frequently,
such as cognitive impairment (13% of patients) and encephalop-
athy/stroke-like events (10% of patients). Cardiac complications
were rare (10%) and non-fatal. Disturbance in renal function was
present in three patients, resulting from obstructive uropathy (two
patients) and glomerulonephritis (one patient), with no reports of
proximal renal tubulopathy, a common finding in children with
RRM2B mutations and mitochondrial DNA depletion.
Two patients developed solid tumours (Patient 12 had oral car-
cinoma, and Patient 18 had breast carcinoma). RRM2B is a gene
not only involved in mitochondrial DNA replication but also plays a
critical role in DNA damage repair. p53R2, a p53-inducible homo-
logue of the R2 subunit of ribonucleotide reductase, has been
evaluated in different cancer types and is known to play a critical
role in DNA damage repair and cancer cell proliferation (Zhang
et al., 2011). These data may suggest abnormalities in DNA repair;
however, it is not possible to conclude whether RRM2B mutations
are oncogenic, owing to small sample size and lack of mutational
analysis of tumour tissue.
To further understand the functional consequence of the
RRM2B mutations identified, we mapped the positions of the
mutated amino acids on the tertiary p53R2 structure (Smith
et al., 2009) (Fig. 5). Many of the missense mutations identified
appear likely to affect the iron-binding properties of p53R2, and
hence impair the catalytic capability of the functional heterotetra-
mer (two p53R2 subunits and two R1 subunits). Gly195, Phe202
and Ile224 are located around the iron-binding pocket. Although
the effect of Phe202Leu may be orchestrated through subtle
hydrophobic contacts, the effect of amino acids Gly195 and
Ile224 is more blatant. Positioned adjacent to amino acids that
contribute to the iron coordination environment, substitutions at
these locations (p.Gly195Arg and p.Ile224Ser) will influence their
amino acid neighbours and alter the coordination of the iron
atom(s). Previous molecular modelling has indicated that
p.Arg41Gln prevents formation of a salt bridge that is important
in conformational changes that control iron binding (Smith et al.,
2009; Pitceathly et al., 2011). p.Arg41Trp is also predicted to
prevent formation of this salt bridge. Arg211 forms a salt bridge
to Glu85, which is thought to be important in stabilization of the
di-iron form (Smith et al., 2009; Pitceathly et al., 2011), and
therefore p.Arg211Lys may also destabilize the di-iron subunit.
Thr144, Arg186, Thr218 and Gly273 are all located at the end
of, or between in the case of Gly273, -helices and appear to
Figure 4 Molecular analysis of the novel c.48G4A (p.Glu16Glu) RRM2B mutation. (A) Schematic showing the location of primers and
the c.48G4A mutation within RRM2B exons 1 and 2. (B) Agarose gel electrophoresis of amplified complementary DNA from Patient 1 (P)
and a normal age-matched control (N) alongside a 123-bp molecular weight marker (M), with the position of normally spliced (303 bp)
and aberrantly spliced (571, 770 and 821 bp) products indicated. (C) Sequencing of the normally spliced complementary DNA product
from Patient 2 reveals that this product is exclusively derived from the normal c.48G allele (equivalent results for Patients 1 and 1.1 not
shown). (D) Example of a sequencing trace of the aberrantly spliced products (571-bp fragment from Patient 2 is shown), demonstrating
that these are almost exclusively derived from the mutant c.48G4A allele.
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stabilize the orientation of the helices. Mutation of these four
amino acids may reduce protein folding efficiency and is asso-
ciated with autosomal-recessive disease in our cohort. The effect
of the p.Asp70Asn mutation cannot readily be predicted, as Asp70
lies in a poorly understood region of the protein between two
helices. p.Ala349Gly could not be modelled because the crystal
structure does not include the C-terminal portion of the protein.
However, Ala349 is located within a conserved heptapeptide
(amino acids 345–351) required for interaction with the R1 sub-
unit (Tyynismaa et al., 2009), and loss of this heptapeptide has
been proposed as the pathological basis of the exon 9 truncating
mutations (Tyynismaa et al., 2009).
There was a clear relationship between phenotypic severity and
genotype in the patients studied. Individuals harbouring recessively
inherited compound heterozygous RRM2B mutations (Patients 19,
20, 21 and 22) presented at an earlier age (mean age of onset 7
years) with a more severe and multisystem disorder, whereas pa-
tients with single heterozygous mutations, inferring autosomal-
dominant transmission, had a later average age of disease onset
(46 years), as is seen with PEO1 mutations (Horvath et al., 2006),
and developed a predominantly myopathic phenotype consisting of
PEO, ptosis, proximal muscle weakness and bulbar dysfunction,
with exceptions noted (Patients 3 and 14). The distinction between
recessively and dominantly inherited mutations was also evident on
histochemical analysis of skeletal muscle tissue, in which COX-
deficient fibres were much more widespread in patients with reces-
sively inherited compound heterozygous mutations (Fig. 1).
Clinical syndromes caused by dysfunction of the nuclear main-
tenance genes can be broadly classified into two groups: (i) mu-
tations that cause mitochondrial DNA depletion, which are at the
most severe end of the phenotypic spectrum; and (ii) mutations
that predispose to accumulation of multiple mitochondrial DNA
deletions. The latter is further subdivided into: (a) recessively in-
herited disease, which presents during childhood with multisystem
involvement; and (b) dominantly inherited disease, which is milder,
typically develops in adulthood, and is often tissue-specific. A
review of the literature suggests RRM2B generally conforms to
these basic principles. The most severe form of RRM2B-related
mitochondrial disease is associated with mitochondrial DNA deple-
tion (Bourdon et al., 2007; Bornstein et al., 2008; Acham-Roschitz
et al., 2009; Kolberg et al., 2009; Spinazzola et al., 2009). Clinical
presentation occurs in the first 6 months of life, with a multisystem
disorder characterized by muscle hypotonia and weakness, seiz-
ures, gastrointestinal dysmotility, respiratory insufficiency, hearing
loss, lactic acidosis, renal tubulopathy and early childhood mortal-
ity. The first reported adult-onset case was in a 30-year-old
female with mitochondrial neurogastrointestinal encephalopathy
who harboured compound heterozygous missense mutations in
RRM2B and mitochondrial DNA depletion (Shaibani et al.,
2009). RRM2B mutations were subsequently associated with mul-
tiple mitochondrial DNA deletions in two large unrelated families
with autosomal-dominant PEO and an identical heterozygous non-
sense mutation that caused truncation of the translated p53R2
protein (Tyynismaa et al., 2009). Further reports have
Figure 5 Location of missense RRM2B mutations on crystal structure. An image of the p53R2 dimer structure is shown (Protein Data
Bank code 3HF1). The locations of 11 of the 12 amino acids altered by missense mutations identified in this study are shown on the di-iron
bound (active) subunit (it has not been possible to illustrate Ala349, as the C-terminus is absent from the crystal structure). The physical
space occupied by these 11 amino acids is illustrated by a multicoloured mesh, with blue indicating positive charge, red indicating negative
charge and yellow indicating neutral. Iron atoms are represented as red spheres.
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demonstrated RRM2B mutations with Kearns–Sayre syndrome
and sporadic/familial PEO (Fratter et al., 2011; Pitceathly et al.,
2011).
There are, however, notable exceptions to these rules. First,
RRM2B-related mitochondrial DNA depletion can potentially
cause a relatively mild clinical phenotype (Shaibani et al., 2009);
and second, identical RRM2B mutations are associated with a
varied phenotypic severity, depending on whether they exist in
homozygous, compound heterozygous or heterozygous states.
We attempt to explain the latter finding using molecular modelling
of the RRM2B missense mutations identified in this study, which
suggests the variants can be broadly divided into two groups:
mutations that severely impair ribonucleotide reductase activity
and cause autosomal-dominant disease through a dominant-nega-
tive effect; and mutations associated with autosomal-recessive dis-
ease, which are predicted to result in moderately decreased
catalytic activity or decreased levels of functional protein through
reduced protein folding efficiency. This is likely to be a conse-
quence of the heterotetrameric structure of ribonucleotide reduc-
tase, which predisposes the enzyme to both a dominant-negative
effect (competitive binding and inactivation of the enzyme) or a
gain-of-function effect (competitive binding with altered function
of the enzyme), alongside the loss of enzymatic activity that
occurs with recessively inherited disease. There is also evidence
that impaired assembly of the multiprotein structures occurs with
some mutations, and there may be a dosage effect, whereby
wild-type p53R2 appears to partially compensate for the mutant
allele, thus ameliorating the clinical phenotype when present in a
heterozygous state (Pitceathly et al., 2011). This phenomenon is
demonstrated in the present study by the p.Ile224Ser, c.48G4A,
p.Arg41Gln and p.Arg211Lys variants. These four variants are
associated with relatively late-onset PEO (fourth to eighth dec-
ades) and multiple mitochondrial DNA deletions when present as
the only heterozygous change, as in Patients 1, 1.1, 2, 3, 7 and 8.
However, when homozygous or compound heterozygous, these
variants are associated with much more severe multisystem dis-
ease, either with mitochondrial DNA depletion in the case of
p.Ile224Ser (homozygote reported by Bornstein et al., 2008) and
c.48G4A (compound heterozygous with another pathogenic
RRM2B mutation, Oxford Molecular Genetics Laboratory, unpub-
lished data), or with multiple mitochondrial DNA deletions in the
case of p.Arg41Gln and p.Arg211Lys (compound heterozygous
patient reported by Pitceathly et al., 2009, and Patient 21 in
this study, respectively).
Our data support previous reports that RRM2B mutations can
present with a PEO-plus/Kearns–Sayre syndrome phenotype akin
to single mitochondrial DNA deletion disorders (Pitceathly et al.,
2011). Patients 19, 20, 21 and 22 all developed symptoms before
the age of 20 years, with PEO and other features suggestive of
Kearns–Sayre syndrome, such as hearing loss, cerebellar ataxia
and endocrine disturbance, although pigmentary retinopathy and
heart block were absent. We would, therefore, recommend
RRM2B over POLG and PEO1 genetic analysis in patients with
PEO-plus or Kearns–Sayre syndrome before a muscle biopsy is per-
formed to exclude a single mitochondrial DNA deletion, if there is a
Mendelian pattern of inheritance. RRM2B analysis should also be
considered in patients with mitochondrial neurogastrointestinal
encephalopathy if blood/urinary deoxyuridine and thymidine levels
are undetectable and thymidine phosphorylase activity is normal in
white cells and platelets, based on the previous report of mitochon-
drial neurogastrointestinal encephalopathy secondary to compound
heterozygous missense mutations in RRM2B (Shaibani et al., 2009),
Case 20 reported here and because gastrointestinal symptoms were
a prominent finding in our cohort of adult patients.
Finally, we report the novel c.48G4A RRM2B variant and pro-
vide evidence to support its pathogenicity through aberrant spli-
cing, partial intron retention and premature termination of
translation and hence predicted absence of any functional protein
from this allele. We report two families (Patients 1, 1.1 and 2)
where heterozygosity for c.48G4A is associated with adult-onset
mitochondrial disease. Because all other RRM2B mutations re-
ported to date in this disease group are either missense or exon
9 truncating, our data further expand the molecular heterogeneity
of RRM2B-related adult mitochondrial disease.
Conclusion
Prioritizing which nuclear-encoded mitochondrial maintenance
genes to screen in adults with multiple mitochondrial DNA dele-
tions is challenging. These data provide the physician with import-
ant clinical information regarding the phenotypic spectrum of
RRM2B-related adult mitochondrial disease and should help
guide genetic diagnosis and enable tailored counselling regarding
potential disease progression. PEO, ptosis and proximal muscle
weakness are well recognized as the predominant clinical features
seen in adult patients with POLG and PEO1 (C10ORF2; Twinkle)
mutations. Bulbar dysfunction, hearing loss and gastrointestinal
problems, including irritable bowel syndrome-like symptoms and
low body mass index, are also additional discriminatory features
seen in RRM2B-related mitochondrial disease and appear to occur
more often than with the other individual nuclear-encoded mito-
chondrial maintenance genes. CNS involvement, characteristic of
other syndromic presentations of mitochondrial disease, is present
less frequently. Thus, the prominence of bulbar dysfunction,
gastrointestinal problems and hearing loss, in the absence of con-
spicuous CNS features, would support early prioritization of
screening of RRM2B over POLG and PEO1 in adults with PEO
and muscle-restricted multiple mitochondrial DNA deletions.
Furthermore, RRM2B gene analysis should be considered early in
Kearns–Sayre syndrome where there is evidence of multiple mito-
chondrial DNA deletions in skeletal muscle or when there appears
to be a Mendelian pattern of inheritance. Finally, RRM2B screen-
ing should be considered in patients with mitochondrial neurogas-
trointestinal encephalopathy when deoxyuridine and thymidine
levels in both blood and urine are negative, thymidine phosphor-
ylase activity is normal in white cells and platelets and analysis of
the TYMP gene does not identify causative mutations.
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